Earnings Summary

Supernus Pharmaceuticals Inc’s revenue fell -1.8% since last year same period to $164.31Mn in the Q4 2023. On a quarterly growth basis, Supernus Pharmaceuticals Inc has generated 6.78% jump in its revenue since last 3-months.

Supernus Pharmaceuticals Inc’s net profit fell -95.39% since last year same period to $1.18Mn in the Q4 2023. On a quarterly growth basis, Supernus Pharmaceuticals Inc has generated 107.35% jump in its net profits since last 3-months.

Supernus Pharmaceuticals Inc’s net profit margin fell -95.3% since last year same period to 0.72% in the Q4 2023. On a quarterly growth basis, Supernus Pharmaceuticals Inc has generated 106.89% jump in its net profit margins since last 3-months.

Supernus Pharmaceuticals Inc’s price-to-earnings ratio after this Q4 2023 earnings stands at 1485.5.

Supernus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at 0.38 - a -30.91% fall from last quarter’s estimates.

Supernus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at 0.38.

Supernus Pharmaceuticals Inc’s earning per share (EPS) jumped 106.98% since last year same period to 0.89 in the Q4 2023. This indicates that the Supernus Pharmaceuticals Inc has generated 106.98% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Supernus Pharmaceuticals Inc’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Supernus Pharmaceuticals Inc’s return on equity (ROE) stands at 0.